Curated News
By: NewsRamp Editorial Staff
September 23, 2026
Lantern Pharma to Unveil OMAI AI Growth Plan in Live Webinar
TLDR
- Lantern Pharma investors gain early access to OMAI growth strategy and benchmarks that could sharpen competitive positioning in AI drug development.
- Lantern Pharma will detail how its multi-agentic OMAI platform, launched as withZeta.ai, expands from rare cancers into more diseases and drug stages.
- Lantern Pharma advances AI-driven drug development to help patients receive more precise oncology therapies and faster hope for rare cancers.
- Lantern Pharma webinar today covers OMAI's AI drug platform, live demo, Q&A, and plans beyond rare cancers.
Impact - Why it Matters
The webinar will provide critical insights into how Lantern Pharma's Open-Medicine AI subsidiary plans to commercialize a multi-agentic AI platform for drug development, potentially accelerating the pace and reducing the cost of bringing new therapies to market. For investors, the session offers a rare look at the platform's economics, benchmarks, and partnership strategy, which could influence the company's valuation and competitive positioning in the rapidly evolving AI-driven biopharma landscape. As AI continues to transform oncology research, Lantern's progress with OMAI and its RADR platform may signal broader shifts in how precision medicines are discovered and developed, ultimately impacting patient access to targeted treatments.
Summary
Lantern Pharma (NASDAQ: LTRN) is hosting a live webinar today at 12:30 p.m. Eastern to unveil the growth plan for Open-Medicine AI ("OMAI"), its wholly owned subsidiary developing a multi-agentic AI platform for drug development. CEO Panna Sharma will lead the 45-minute session, covering OMAI's market opportunity, customer feedback, platform capabilities, development roadmap, economics, benchmarks, potential partnerships, and contribution to shareholder value. The webinar will include a live demonstration followed by a question-and-answer session.
OMAI's core capabilities and initial platform were developed within Lantern's clinical programs and areas of focus. Launched as withZeta.ai in April 2026 with an initial focus on rare cancers, the platform is now expanding into additional diseases, therapy types, and stages of drug development. Lantern Pharma is a clinical-stage biopharmaceutical company leveraging its proprietary RADR artificial intelligence and machine-learning platform to transform the cost, pace, and precision of oncology drug development. By integrating large-scale genomic and biological data with advanced machine learning, RADR is designed to identify the patients most likely to benefit from Lantern's therapies and guide biomarker-driven clinical development. The company's pipeline includes LP-184 (zirdafulven), LP-300, and LP-284, along with its central-nervous-system-focused subsidiary, Starlight Therapeutics, and its AI subsidiary, Open-Medicine AI.
For more information, the full press release is available at https://ibn.fm/SpEDF. The latest news and updates relating to LTRN are available in the company's newsroom at https://ibn.fm/LTRN. This announcement was distributed via AINewsWire, a specialized communications platform focused on AI advancements and part of the Dynamic Brand Portfolio @ IBN, which offers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution via IBN, and a full array of tailored corporate communications solutions.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Lantern Pharma to Unveil OMAI AI Growth Plan in Live Webinar
